Bladeless all-laser cataract surgery offers several advantages

Article

A novel surgical technique using two lasers has been introduced offering several potential advantages for cataract surgery, according to recently published data in the journal Clinical Ophthalmology.

A novel surgical technique using two lasers has been introduced offering several potential advantages for cataract surgery, according to recently published data in the journal Clinical Ophthalmology.

The study, by Dr A. John Kanellopoulos (LaserVision gr Institute, Athens, Greece), examined the safety and efficacy of cataract extraction using a bladeless all-laser technique that combines femtosecond and nanosecond lasers. In this study, a female patient of 57 years of age underwent cataract extraction using the two lasers and standard phacoemulsification.

To perform the corneal incision, capsulorhexis and initial lens fragmentation in each eye, Dr Kanellopoulos used the femtosecond laser. Then he employed the nanosecond laser to enter the 2.8 mm incision, uni-axially, complete the viscoelastic-divided nucleus fragment emulsification and removal in one eye, while the other eye was completed using phacoemulsification.

Both eyes were implanted with a foldable acrylic intraocular lens in the posterior chamber. The perioperative acuity, refraction, keratometry, Scheimpflug tomography, intraocular pressure, endothelial cell counts and total energy used with each laser were analysed.

After 6 months, the patient's corrected distance visual acuity improved from 20/60 and 20/70 pre-op to 20/20 in both eyes. The total intraocular energy used was slightly different, with 2 J being ued by the femtosecond laser in both eyes but 6 J were used by the phacoemulsification device in the right eye and 2.4 J by the nanosecond laser in the left eye. This alternative technique was therefore, deemed to offer several potential advantages, including lower intraocular energy use and elimination of the possibility of corneal thermal injury.

For more detailed information please view the abstract here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.